19-53050034-A-T
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_001191055.2(ERVV-2):c.783A>T(p.Gln261His) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 10/16 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Consequence
NM_001191055.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ERVV-2 | NM_001191055.2 | c.783A>T | p.Gln261His | missense_variant | 2/2 | ENST00000601417.3 | NP_001177984.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ERVV-2 | ENST00000601417.3 | c.783A>T | p.Gln261His | missense_variant | 2/2 | 4 | NM_001191055.2 | ENSP00000472919.1 |
Frequencies
GnomAD3 genomes Cov.: 20
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 20
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jan 26, 2022 | The c.783A>T (p.Q261H) alteration is located in exon 2 (coding exon 1) of the ERVV-2 gene. This alteration results from a A to T substitution at nucleotide position 783, causing the glutamine (Q) at amino acid position 261 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.